Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: an integrated analysis of Phase II/III Clinical Development Programs

Research output

Research output per year 2019 2019 2019

• 34 Citations
• 1 Comment/debate

Research output per year

Research output per year

Search results

• 2019

  Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

  Ghosh, S., Gensler, L. S., Yang, Z., Gasink, C., Chakravarty, S. D., Farahi, K., Ramachandran, P., Ott, E. & Strober, B. E., 4 Jun 2019, In: Drug Safety. 42, 6, p. 809 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Ustekinumab 100%
  • Psoriatic Arthritis 80%
  • Psoriasis 65%
  • Crohn Disease 63%
  • Safety 57%
  4 Citations (Scopus)